Pharmacologic Treatments and Supportive Care for Middle East Respiratory Syndrome
Open Access
- 1 June 2020
- journal article
- research article
- Published by Centers for Disease Control and Prevention (CDC) in Emerging Infectious Diseases
- Vol. 26 (6), 1102-1112
- https://doi.org/10.3201/eid2606.200037
Abstract
Pharmacologic Treatments for MERSKeywords
This publication has 35 references indexed in Scilit:
- Characteristics and Outcomes of Middle East Respiratory Syndrome Coronavirus Patients Admitted to an Intensive Care Unit in Jeddah, Saudi ArabiaJournal of Intensive Care Medicine, 2015
- Ribavirin and interferon alfa-2a for severe Middle East respiratory syndrome coronavirus infection: a retrospective cohort studyThe Lancet Infectious Diseases, 2014
- Clinical Course and Outcomes of Critically Ill Patients With Middle East Respiratory Syndrome Coronavirus InfectionAnnals of Internal Medicine, 2014
- Ribavirin and interferon therapy in patients infected with the Middle East respiratory syndrome coronavirus: an observational studyInternational Journal of Infectious Diseases, 2014
- Treatment with interferon-α2b and ribavirin improves outcome in MERS-CoV–infected rhesus macaquesNature Medicine, 2013
- Epidemiological, demographic, and clinical characteristics of 47 cases of Middle East respiratory syndrome coronavirus disease from Saudi Arabia: a descriptive studyThe Lancet Infectious Diseases, 2013
- Inhibition of novel β coronavirus replication by a combination of interferon-α2b and ribavirinScientific Reports, 2013
- Isolation of a Novel Coronavirus from a Man with Pneumonia in Saudi ArabiaNew England Journal of Medicine, 2012
- GRADE: an emerging consensus on rating quality of evidence and strength of recommendationsBMJ, 2008
- Anti-inflammatory effects of macrolides—an underappreciated benefit in the treatment of community-acquired respiratory tract infections and chronic inflammatory pulmonary conditions?Journal of Antimicrobial Chemotherapy, 2005